Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $85M | $-152M | $-140M | $-110M | -27.7% | 230194.6% | -12.9% |
| 2024 | $0M | $-181M | $-161M | $-138M | -31.5% | -99.8% | 59.5% |
| 2023 | $21M | $-107M | $-101M | $-79M | -32.8% | 562.3% | -6.2% |
| 2022 | $3M | $-106M | $-107M | $-98M | -46.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 85.21 |
| Operating Revenue | 85.21 |
| Operating Expense | 244.76 |
| Research And Development | 195.70 |
| Selling General And Administration | 49.06 |
| Total Expenses | 244.76 |
| Operating Income | -159.55 |
| Total Operating Income As Reported | -159.55 |
| EBITDA | -151.92 |
| Normalized EBITDA | -151.92 |
| EBIT | -159.55 |
| Interest Income | 19.48 |
| Net Interest Income | 19.48 |
| Other Non Operating Income Expenses | -0.04 |
| Other Income Expense | -0.04 |
| Interest Income Non Operating | 19.48 |
| Net Non Operating Interest Income Expense | 19.48 |
| Pretax Income | -140.11 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -140.11 |
| Net Income From Continuing And Discontinued Operation | -140.11 |
| Net Income From Continuing Operation Net Minority Interest | -140.11 |
| Net Income | -140.11 |
| Net Income Common Stockholders | -140.11 |
| Net Income Including Noncontrolling Interests | -140.11 |
| Normalized Income | -140.11 |
| Diluted NI Availto Com Stockholders | -140.11 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 7.62 |
| General And Administrative Expense | 49.06 |
| Other Gand A | 49.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc.this co. | FDMT | $523M | -3.73 | 1.03 | -27.7% | -3.19 |
| Tectonic Therapeutic, Inc. | TECX | $550M | -7.41 | 2.19 | -29.5% | -4.16 |
| Strata Critical Medical, Inc. | SRTA | $542M | 13.10 | 1.94 | 14.8% | -36.28 |
| XOMA Royalty Corporation | XOMA | $532M | 16.77 | 6.34 | 37.8% | 12.14 |
| Aquestive Therapeutics, Inc. |
| 2021 | - | - | - | - | - | - | - |
| AQST |
| $519M |
| -6.20 |
| -15.43 |
| 248.9% |
| -6.66 |
| Pacific Biosciences of California, Inc. | PACB | $506M | -0.93 | 94.65 | -10214.5% | -7.50 |
| Arvinas, Inc. | ARVN | $499M | -6.18 | 1.15 | -18.6% | -3.23 |
| AngioDynamics, Inc. | ANGO | $497M | -14.62 | 2.72 | -18.6% | 256.27 |
| Standard BioTools Inc. | LAB | $496M | -6.62 | 1.17 | -17.7% | -4.73 |
| Peer Median | - | -6.19 | 2.06 | -18.1% | -4.45 | |